These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 16244359)

  • 1. The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers.
    Colilla S; Kantoff PW; Neuhausen SL; Godwin AK; Daly MB; Narod SA; Garber JE; Lynch HT; Brown M; Weber BL; Rebbeck TR
    Carcinogenesis; 2006 Mar; 27(3):599-605. PubMed ID: 16244359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The AIB1 glutamine repeat polymorphism is not associated with risk of breast cancer before age 40 years in Australian women.
    Montgomery KG; Chang JH; Gertig DM; Dite GS; McCredie MR; Giles GG; Southey MC; Hopper JL; Campbell IG
    Breast Cancer Res; 2005; 7(3):R353-6. PubMed ID: 15987430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene.
    Hughes DJ; Ginolhac SM; Coupier I; Barjhoux L; Gaborieau V; Bressac-de-Paillerets B; Chompret A; Bignon YJ; Uhrhammer N; Lasset C; Giraud S; Sobol H; Hardouin A; Berthet P; Peyrat JP; Fournier J; Nogues C; Lidereau R; Muller D; Fricker JP; Longy M; Toulas C; Guimbaud R; Yannoukakos D; Mazoyer S; Lynch HT; Lenoir GM; Goldgar DE; Stoppa-Lyonnet D; Sinilnikova OM
    Int J Cancer; 2005 Nov; 117(2):230-3. PubMed ID: 15900600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history.
    Rebbeck TR; Wang Y; Kantoff PW; Krithivas K; Neuhausen SL; Godwin AK; Daly MB; Narod SA; Brunet JS; Vesprini D; Garber JE; Lynch HT; Weber BL; Brown M
    Cancer Res; 2001 Jul; 61(14):5420-4. PubMed ID: 11454686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.
    Spurdle AB; Antoniou AC; Kelemen L; Holland H; Peock S; Cook MR; Smith PL; Greene MH; Simard J; Plourde M; Southey MC; Godwin AK; Beck J; Miron A; Daly MB; Santella RM; Hopper JL; John EM; Andrulis IL; Durocher F; Struewing JP; Easton DF; Chenevix-Trench G; ; ; ; ; ;
    Cancer Epidemiol Biomarkers Prev; 2006 Jan; 15(1):76-9. PubMed ID: 16434590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphic CAG/CAA repeat length in the AIB1/SRC-3 gene and prostate cancer risk: a population-based case-control study.
    Hsing AW; Chokkalingam AP; Gao YT; Wu G; Wang X; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Chiang T; Chen YL; Stanczyk FZ; Chang C
    Cancer Epidemiol Biomarkers Prev; 2002 Apr; 11(4):337-41. PubMed ID: 11927493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyglutamine repeat length in the NCOA3 does not affect risk in familial breast cancer.
    Wilkening S; Burwinkel B; Grzybowska E; Klaes R; Pamula J; Pekala W; Zientek H; Hemminki K; Försti A
    Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):291-2. PubMed ID: 15668512
    [No Abstract]   [Full Text] [Related]  

  • 9. The RAD51 135 G>C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers.
    Jakubowska A; Gronwald J; Menkiszak J; Górski B; Huzarski T; Byrski T; Edler L; Lubiñski J; Scott RJ; Hamann U
    Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):270-5. PubMed ID: 17301259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physical activity and the risk of breast cancer in BRCA1/2 mutation carriers.
    Pijpe A; Manders P; Brohet RM; Collée JM; Verhoef S; Vasen HF; Hoogerbrugge N; van Asperen CJ; Dommering C; Ausems MG; Aalfs CM; Gomez-Garcia EB; ; Van't Veer LJ; van Leeuwen FE; Rookus MA
    Breast Cancer Res Treat; 2010 Feb; 120(1):235-44. PubMed ID: 19680614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective study of XRCC1 (X-ray cross-complementing group 1) polymorphisms and breast cancer risk.
    Patel AV; Calle EE; Pavluck AL; Feigelson HS; Thun MJ; Rodriguez C
    Breast Cancer Res; 2005; 7(6):R1168-73. PubMed ID: 16457697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
    Metcalfe K; Lynch HT; Ghadirian P; Tung N; Olivotto I; Warner E; Olopade OI; Eisen A; Weber B; McLennan J; Sun P; Foulkes WD; Narod SA
    J Clin Oncol; 2004 Jun; 22(12):2328-35. PubMed ID: 15197194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. XRCC1 and XPD genetic polymorphisms, smoking and breast cancer risk in a Finnish case-control study.
    Metsola K; Kataja V; Sillanpää P; Siivola P; Heikinheimo L; Eskelinen M; Kosma VM; Uusitupa M; Hirvonen A
    Breast Cancer Res; 2005; 7(6):R987-97. PubMed ID: 16280050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers: association with breast/ovarian cancer phenotype.
    Dagan E; Friedman E; Paperna T; Carmi N; Gershoni-Baruch R
    Eur J Hum Genet; 2002 Nov; 10(11):724-8. PubMed ID: 12404104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CYP1A2 genotype modifies the association between coffee consumption and breast cancer risk among BRCA1 mutation carriers.
    Kotsopoulos J; Ghadirian P; El-Sohemy A; Lynch HT; Snyder C; Daly M; Domchek S; Randall S; Karlan B; Zhang P; Zhang S; Sun P; Narod SA
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):912-6. PubMed ID: 17507615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of NCOA3 polymorphisms with breast cancer risk.
    Burwinkel B; Wirtenberger M; Klaes R; Schmutzler RK; Grzybowska E; Försti A; Frank B; Bermejo JL; Bugert P; Wappenschmidt B; Butkiewicz D; Pamula J; Pekala W; Zientek H; Mielzynska D; Siwinska E; Bartram CR; Hemminki K
    Clin Cancer Res; 2005 Mar; 11(6):2169-74. PubMed ID: 15788663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer.
    Pierce LJ; Levin AM; Rebbeck TR; Ben-David MA; Friedman E; Solin LJ; Harris EE; Gaffney DK; Haffty BG; Dawson LA; Narod SA; Olivotto IA; Eisen A; Whelan TJ; Olopade OI; Isaacs C; Merajver SD; Wong JS; Garber JE; Weber BL
    J Clin Oncol; 2006 Jun; 24(16):2437-43. PubMed ID: 16636335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The CASP8 rs3834129 polymorphism and breast cancer risk in BRCA1 mutation carriers.
    Catucci I; Verderio P; Pizzamiglio S; Manoukian S; Peissel B; Zaffaroni D; Roversi G; Ripamonti CB; Pasini B; Barile M; Viel A; Giannini G; Papi L; Varesco L; Martayan A; Riboni M; Volorio S; Radice P; Peterlongo P
    Breast Cancer Res Treat; 2011 Feb; 125(3):855-60. PubMed ID: 20652397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women.
    MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk
    Breast Cancer Res Treat; 2010 Apr; 120(3):727-36. PubMed ID: 19672706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study.
    Chang-Claude J; Andrieu N; Rookus M; Brohet R; Antoniou AC; Peock S; Davidson R; Izatt L; Cole T; Noguès C; Luporsi E; Huiart L; Hoogerbrugge N; Van Leeuwen FE; Osorio A; Eyfjord J; Radice P; Goldgar DE; Easton DF; ; ; ;
    Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):740-6. PubMed ID: 17416765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.